Skip to main content

Integrating chemical and biological approaches to target NAD production and signaling in cancer

Objective

Deregulated nicotinamide adenine dinucleotide (NAD) biosynthesis and signaling underlies many aspects of carcinogenesis. NAD biosynthetic enzymes, such as nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT), are commonly upregulated in cancer cells, where they fuel increased metabolic demands and downstream enzymes involved in DNA repair and in the promotion of cell growth, cell motility, de-differentiation and immune escape. In addition, NAD-producing enzymes, such as NAMPT, moonlight in the extracellular space, exerting strongly pro-oncogenic, autocrine and paracrine effects. Many of these roles of NAD-producing and NAD-utilizing enzymes appear to be shared between solid and haematological cancers. Thus, agents targeting NAD production or signaling are expected to have broad applicability. INTEGRATA will: 1. develop new NAD biosynthesis and NAD/nucleotide signaling inhibitors; 2. assess pharmacology and toxicity of the new therapeutics in preclinical models; 3. achieve the proof-of-concept of activity of the newly generated agents in relevant in vivo cancer models. INTEGRATA will train 14 PhD students in an overarching, interdisciplinary training programme that will include training-by-research, joint courses of technical, scientific, and transferrable skills, active participation to public scientific events, and an intense intersectoral networking exchange plan. The INTEGRATA Consortium encompasses academic institutions, research centres, and SMEs/biotech pharma, all with proven experience in higher education and training, and geared with state-of-the-art scientific and technical expertise and infrastructures.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/basic medicine/pharmacology and pharmacy
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/enzymes

Call for proposal

H2020-MSCA-ITN-2018
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

UNIVERSITA DEGLI STUDI DI GENOVA
Address
Via Balbi 5
16126 Genova
Italy
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 522 999,36

Participants (12)

UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 252 788,40
Address
Venusberg-campus 1
53127 Bonn
Activity type
Higher or Secondary Education Establishments
THE UNIVERSITY OF SHEFFIELD
United Kingdom
EU contribution
€ 303 172,56
Address
Firth Court Western Bank
S10 2TN Sheffield
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Switzerland
EU contribution
€ 281 276,64
Address
Rue Du Bugnon 21
1011 Lausanne
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 281 276,64
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI TORINO
Italy
EU contribution
€ 261 499,68
Address
Via Giuseppe Verdi 8
10124 Torino
Activity type
Higher or Secondary Education Establishments
UNIVERSIDAD DE SEVILLA
Spain
EU contribution
€ 250 904,88
Address
Calle S. Fernando 4
41004 Sevilla
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI TRENTO
Italy
EU contribution
€ 261 499,68
Address
Via Calepina 14
38122 Trento
Activity type
Higher or Secondary Education Establishments
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany
EU contribution
€ 252 788,40
Address
Martinistrasse 52
20251 Hamburg
Activity type
Higher or Secondary Education Establishments
UNIVERSITE DE MONTPELLIER
France
EU contribution
€ 274 802,04
Address
163 Rue Auguste Broussonnet
34090 Montpellier
Activity type
Higher or Secondary Education Establishments
INNOVAMOL CONSULTING SRL
Italy
EU contribution
€ 261 499,68
Address
Viale Alfeo Corassori 24
41124 Modena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NOVIMMUNE SA
Switzerland
EU contribution
€ 281 276,64
Address
Chemin Des Aulx 14
1228 Plan Les Ouates Geneve
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HEIDELBERG PHARMA RESEARCH GMBH
Germany
EU contribution
€ 252 788,40
Address
Schriesheimer Strasse 101
68526 Ladenburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Partners (2)

UNIVERSITE DE LAUSANNE
Switzerland
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
INNOVATION ACTA S.R.L.
Italy
Address
Via D.a. Azuni, 9
00196 Roma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)